Valeo Financial Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Valeo Financial Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-84	Closed	-$14K	–	2175
2020 Q4	$14K	Sell	84 -100	-54%	-$14.8K	﹤0.01%	1119
2020 Q3	$26K	Sell	184 -94	-34%	-$14.3K	﹤0.01%	856
2020 Q2	$45K	Buy	278 +2	+0.7%	+$272	﹤0.01%	772
2020 Q1	$29K	Sell	276 -3	-1%	-$343	﹤0.01%	781
2019 Q4	$36K	Hold	279	–	–	﹤0.01%	766
2019 Q3	$21K	Hold	279	–	–	﹤0.01%	839
2019 Q2	$42K	Sell	279 -3	-1%	-$365	﹤0.01%	655
2019 Q1	$34K	Buy	282 +75	+36%	+$9.64K	﹤0.01%	650
2018 Q4	$23K	Buy	207 +6	+3%	+$750	﹤0.01%	680
2018 Q3	$25K	Buy	201 +11	+6%	+$1.5K	﹤0.01%	708
2018 Q2	$25K	Hold	190	–	–	﹤0.01%	702
2018 Q1	$14K	Sell	190 -1,000	-84%	-$66.7K	﹤0.01%	840
2017 Q4	$66K	Hold	1,190	–	–	0.01%	425
2017 Q3	$54K	Buy	+1,190	New	+$47.6K	0.01%	398

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Valeo Financial Advisors's SRPT Position: Q1 2021 in Review

Valeo Financial Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 84 shares — an estimated $14K sold.

Valeo Financial Advisors first reported a position in SRPT in Q3 2017 and held it in 14 quarters. The position peaked at $66K in Q4 2017. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

Valeo Financial Advisors reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
Valeo Financial Advisors sold 84 Sarepta Therapeutics shares in Q1 2021, an estimated $14K.
Valeo Financial Advisors first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 14 quarters.
Valeo Financial Advisors's Sarepta Therapeutics position peaked at $66K in Q4 2017.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Valeo Financial Advisors's 13F filing for Q1 2021, filed 12 Apr 2021.